After scoring big Pfizer buyout, a Therachon co-founder turns once again to dwarfism with $24M Series A

Less than two years after selling her first biotech to Pfizer for a hefty $810 million, a French researcher has launched a new gene therapy …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Af­ter scor­ing big Pfiz­er buy­out, a Ther­a­chon co-founder turns once again to dwarfism with $24M Se­ries A